WO1991014700A2 - PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION - Google Patents
PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION Download PDFInfo
- Publication number
- WO1991014700A2 WO1991014700A2 PCT/US1991/001863 US9101863W WO9114700A2 WO 1991014700 A2 WO1991014700 A2 WO 1991014700A2 US 9101863 W US9101863 W US 9101863W WO 9114700 A2 WO9114700 A2 WO 9114700A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- ioweralkyi
- phenyl
- defined hereinbefore
- acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 230000008569 process Effects 0.000 title claims abstract description 41
- 230000018044 dehydration Effects 0.000 title description 4
- 238000006297 dehydration reaction Methods 0.000 title description 4
- 150000003431 steroids Chemical class 0.000 claims abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 150000008064 anhydrides Chemical class 0.000 claims abstract description 24
- 150000007524 organic acids Chemical class 0.000 claims abstract description 14
- 239000012445 acidic reagent Substances 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 150000001266 acyl halides Chemical class 0.000 claims abstract description 9
- 239000000543 intermediate Substances 0.000 claims abstract description 9
- 239000003513 alkali Substances 0.000 claims abstract description 7
- 239000011260 aqueous acid Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000004423 acyloxy group Chemical group 0.000 claims description 13
- 150000002431 hydrogen Chemical group 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 229910007161 Si(CH3)3 Inorganic materials 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 4
- 150000002081 enamines Chemical class 0.000 claims description 4
- 150000002084 enol ethers Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 abstract description 5
- 239000011541 reaction mixture Substances 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- -1 fiuoro Chemical group 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 0 CCCCC(CC1)C(CCCC*)C2[C@@]1(C)C([*+])(*)C(*)C2 Chemical compound CCCCC(CC1)C(CCCC*)C2[C@@]1(C)C([*+])(*)C(*)C2 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000370 acceptor Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000011905 homologation Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000006053 organic reaction Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- RMHGCKSCDKUSLM-UHFFFAOYSA-N (5z)-5-diazo-2,3,4,4a,6,7,8,9-octahydrobenzo[7]annulene Chemical compound [N-]=[N+]=C1CCCCC2=CCCCC12 RMHGCKSCDKUSLM-UHFFFAOYSA-N 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- CEMJHSLXAAITIK-QUPIPBJSSA-N 1-[(8r,9s,10s,13s,14s,17r)-17-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone Chemical class C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 CEMJHSLXAAITIK-QUPIPBJSSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- YSMYHWBQQONPRD-UHFFFAOYSA-N 2-chlorofuran Chemical compound ClC1=CC=CO1 YSMYHWBQQONPRD-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- SNMVJSSWZSJOGL-PLOWYNNNSA-N 9alpha-hydroxyandrost-4-en-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@@]3(O)CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 SNMVJSSWZSJOGL-PLOWYNNNSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GHWJPVSCQJPHCK-CQRJNKKSSA-N [2-[(8s,10s,13s,14s,17s)-10,13-dimethyl-2,7,8,12,14,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C1=CCC[C@]2(C)C3=CC[C@]4(C)[C@@H](C(=O)COC(=O)C)CC[C@H]4[C@@H]3CC=C21 GHWJPVSCQJPHCK-CQRJNKKSSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical class [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002419 homosteroids Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- ORSUTASIQKBEFU-UHFFFAOYSA-N n,n-diethylbutan-1-amine Chemical compound CCCCN(CC)CC ORSUTASIQKBEFU-UHFFFAOYSA-N 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- 150000002875 norsteroids Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- VFDOIPKMSSDMCV-UHFFFAOYSA-N pyrrolidine;hydrobromide Chemical compound Br.C1CCNC1 VFDOIPKMSSDMCV-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000005730 ring rearrangement reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Chemical group 0.000 description 1
- 239000010703 silicon Chemical group 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 150000003613 toluenes Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- PNQBEPDZQUOCNY-UHFFFAOYSA-N trifluoroacetyl chloride Chemical compound FC(F)(F)C(Cl)=O PNQBEPDZQUOCNY-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
- C07J7/0055—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Definitions
- the 9 ⁇ -hydroxy (OH) steroids are useful intermediates for preparing corticosteroids. Such corticosteroids are useful for treatment of psoriasis, dermatological diseases and inflammation.
- U.S. Patent 4,127,596 describes a process for dehydrating 9 ⁇ -hydroxysteroid type compounds with a strong acid (pKa less than 1) to give ⁇ 9.II steroids.
- a ⁇ 9.II steroid is one which possesses a double bond between positions 9 and 11 in the steroid ring.
- U.S. Patent 4,102,907 and European Patent Application number 87201933.6 teach dehydration of steroid intermediates. John Fried and John A. Edwards, Organic Reactions in Steroid Chemistry, Vol.
- the present invention is directed towards a process for preparing steroid intermediates of formula (XXX):
- R1 represents -C ⁇ CR 70 wherein R 70 is hydrogen or Si(CH 3 ) 3 , or R 1 is Ioweralkyi, haloalkyl, phenyl or phenylalkyl, -COR 11 , -COOR 1 wherein R 11 represents hydrogen or Ioweralkyi; or R 1 is -COCH2R 12 wherein R 12 represents hydroxy, halo or alkanoyloxy; R 4 represents H or Ioweralkyi, preferably methyl having either the ⁇ or ⁇ stereochemistry; R9 represents hydrogen, fluoro.
- R 10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen, alkoxy, nitro; or R 10 is heteroaryl, alkyl or alkyl substituted with phenyl or halogen.
- -OCOR 10 at position 17 has the ⁇ -stereochemistry.
- the present process comprises contacting a 9 ⁇ -hydroxysteroid of the formula (XX):
- R 1 and R 4 are as defined hereinbefore;
- Z is a group which can be substituted with the -COR 10 moiety, and
- R 5 represents Ioweralkyi or R 1 a R R 3 Si- wherein R 1 a , R 2 and R 3 independently represent Ioweralkyi, phenyl or phenylalkyi; and R 9 is as defined hereinbefore;
- R ⁇ and R 7 independently represent Ioweralkyi or -(CR 20 R 21 ) - and -(CR30R31) W ., respectively, wherein R 20 , R 2 , R30 and R 31 independently represent H, Ioweralkyi, or aryl and w and v independently represent an integer from 0 to 6 and v + w is an integer from 2 to 12, preferably 2, and wherein -(CR 20 R 21 ) V - or -(CR 30 R 31 ) W - are connected together in a ring or through an oxygen or nitrogen atom; and R 9 is as defined hereinbefore;
- R 6 and R 7 are as defined hereinbefore;
- R 9 is as defined hereinbefore;
- the present invention is directed toward a process for preparing novel compounds of the formula:
- R 1 represents -C ⁇ CR 70 wherein R 70 is hydrogen or -Si(CH 3 ) 3 , or R 1 is Ioweralkyi, haloalkyi, phenyl or phenylalkyi, -COR 11 or -COOR 1 wherein R 11 represents Ioweralkyi, hydroxyaikyi or acyloxy, preferably where Ioweralkyi is methyl, hydroxyaikyi is hydroxymethyl and acyloxy is acetoxy; or -COCH2R 12 wherein R 12 represents hydroxy, halo or alkanoyloxy; R 4 represents H or Ioweralkyi, preferably methyl having either the ⁇ or ⁇ stereochemistry; R 4 represents H or Ioweralkyi, preferably methyl having either the ⁇ or ⁇ stereochemistry; R 9 represents hydrogen, fiuoro, chloro or Ioweralkyi and R 10 represents hydrogen, phenyl, phenyl substituted with alkyl, halogen
- R and R 4 are as defined hereinbefore;
- Z is a group which can be substituted with the -COR 10 moiety, and
- R 5 represents " Ioweralkyi or R 1a R 2 R 3 Si- wherein R 1 a , R 2 and R 3 independently represent Ioweralkyi, phenyl or phenylalkyi; and R 9 is as defined hereinbefore;
- R 6 and R 7 independently represent Ioweralkyi or -(CR 20 R 21 ) - and -(CR3°R3 1 ) W -, respectively, wherein R 20 , R 21 , R3° and R3 1 independently represent H, Ioweralkyi, or aryl and w and v independently represent an integer from 0 to 6 and v + w is an integer from 2 to 12, preferably 2, and wherein -(CR 0 R 21 ) V - or -(CR 3 °R31) W - are connected together in a ring or through an oxygen or nitrogen atom; and R 9 is as defined hereinbefore;
- R 6 and R 7 are as defined hereinbefore;
- R 9 , R 10 and R 12 are as defined hereinbefore, the dotted line represents an optional double bond and the numbering system is illustrated for those preferred compounds.
- the present process has the unexpected and surprising advantage of regio-specifically dehydrating the 9 ⁇ -OH to form a ⁇ 9,ll steroid possessing the desired R 10 moiety for the production of such steroids in a single step or reaction vessel.
- the present process also has the advantage of effecting the desired transformation without D-ring rearrangement as described hereinbefore. It is believed that the presence of the 17-ester prevents D-ring homologation (ie. via rearrangement) during the present process. As such, the esterification at position 17 is desirable.
- the compounds of formulas (XXV) and (XXX) are useful intermediates for the production of corticosteroids from the steroid derived compound 9 ⁇ -hydroxyandrost-4-ene-3,17-dione as described hereinbefore.
- the present process also has the advantage of providing a one-step process or a simplified two-step process for preparing the compounds of formula (XXX), whose compounds permit convenient substitution of functional groups at positions 9 and 11.
- the wavy line bond ie. " « ⁇ -" indicates the substituent possesses either the alpha ( ⁇ ) or beta ( ⁇ ) stereochemistry.
- a substituent possessing the ⁇ stereochemistry lies below the plane of the paper, whereas a substituent possessing the ⁇ " * stereochemistry lies above the plane of the paper, as defined in Leland J. Chinn, Paul D. Klimstra, John S. Baran and Raphael Pappo, The Chemistry and Biochemistry of Steroids, Intra-Science Chemistry Reports, Vol. 3 No. 1 , Intra-Science Research Foundation, Santa Monica, California 1969, pp. 1-82.
- the " ⁇ " symbol indicates a methyl substituent possessing the ⁇ stereochemistry.
- alkyl or “loweralkyl”(including the alkyl portion of alkanoyloxy) refers to a straight chain saturated hydrocarbon moiety containing from 1 to 10 carbon atoms, or a branched saturated hydrocarbon moiety of 3 to 10 carbon atoms, such as for example, methyl (ie. -CH3), ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like.
- phenylalkyi refers to a phenyl moiety convarriably bonded to an alkyl moiety of one to six carbon atoms such as, for example, phenylmethyl, 2-phenylethyl and the like.
- heteroaryl refers to a cyclic group having at least one O, S and/or N interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the heteroaryl group having from 2 to 14, preferably from 2 to 14 carbon atoms, e.g., 2-, 3- or 4-pyridyl, 2- or 3- furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-imidazolyl, 2-, 4- or 5- pyrimidinyl, 2-pyrazinyl, 3- or 4-pyridazinyl, 3-, 5- or 6-[1 ,2,4-triazinyl], 3- or 5-[1 ,2,4-thiadizolyl], 2-, 3- classroom 4-, 5-, 6- or 7-benzofuranyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, etc
- Z can represent hydrogen or any protecting group which is sufficiently labile to permit substitution of the -Z moiety with the -COR 10 moiety under the process conditions.
- groups include but are not limited to tetrahydropyranyl, alkoxyalkyl, alkoxyalkyl substituted with halogen, oxygen or silicon ie. 2-(trimethylsilyl)ethoxy- methyl and trisubstituted silyl of the formula -SiR 1 a R 2 R 3 wherein R 1 a , R 2 and R 3 independently represents Ioweralkyi, phenyl or phenylalkyi, preferably -Si(CH3)3.
- R 1 a , R 2 and R 3 independently represents Ioweralkyi, phenyl or phenylalkyi, preferably -Si(CH3)3.
- Other suitable protecting groups are described in Theodora W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, New York, (19
- Step (a) of Process (A) the steroid of formula (XXV) is prepared by contacting the compound of formula (XX) with an anhydride, an organic acid, and an acid reagent having a pKa of about 3 or less, preferably 1 or less.
- Suitable anhydrides are of the formula: (R 10 CO)2 ⁇ wherein R 10 represents hydrogen; phenyl; phenyl substituted with alkyl, halogen, alkoxy or nitro; Ioweralkyi; or Ioweralkyi substituted with phenyl or halogen such as perfluoroalkyl of one to 10 carbon atoms.
- R 10 is methyl or trifluoromethyl (-CF 3 ).
- the anhydride is acetic anhydride or trifluoroacetic anhydride ((CF3CO)2 ⁇ ).
- unsymmetrical anhydrides having differing values for R 10 .
- the anhydride can be contacted with the compound of formula (XX) in a ratio ranging from excess to about equimola ⁇ l (moles of anhydride: mole compound of formula (XX)), more preferably from about 20 to 5:1 , most preferably about 10 to 1 :1.
- Suitable organic acids include acids containing from one to 10 carbon atoms. Such acids can be of the formula R 30 COOH (X) wherein R 30 represents Ioweralkyi, preferably ethyl or Ioweralkyi substituted with halogen, preferably fluoro.
- Representative organic acids include the C-1 to C-10 alkanoic acids such as formic, acetic, propanoic acid, and the like or mixtures thereof, preferably acetic or propanoic.
- the term "organic acid” does not include the same compounds as does the term "acid reagent".
- the organic acid can be contacted with the compound of formula (XX) in a ratio ranging from excess to about equimola ⁇ l (moles of organic acid: mole compound of formula (XX)), more preferably from about 100 to 1 , most preferably from about 35 to 1 :1.
- Suitable acid reagents having a pKa of about 3 or less, preferably about 1 or less include trifluoroacetic acid, para-toluene sulfonic acid, sulfuric acid, perchloric acid, hydrochloric acid, or strong cationic exchange resins possessing sulfonic acid type functionalities, such as described in A.J. Gordon and Richard A. Ford, The Chemist's Companion, A Handbook of Practical Data, Techniques, and References, John Wiley & Sons, New York, New York (1972).
- the acid reagent can be contacted with the compound of formula (XX) in a ratio ranging from 10 to about 0.1 :1 (moles of acid reagent: mole compound of formula (XX)), more preferably from about 10 to 1 :1.
- step (a) in process A is carried out in a solvent.
- suitable solvents include the chlorinated hydrocarbons such as chloroform, dichloromethane, and carbon tetrachloride; and alkane solvents such as hexane or heptane.
- the amount of solvent can range from an excess amount to an amount sufficient to dissolve the reactants, generally about 10 percent volume basis per reaction mixture.
- the order of addition of the starting materials ie. reactants, in the present process is not critical. As such, the reactants can be added in any convenient order or together at about the same time.
- Step (a) can be conducted at ambient pressures and at temperatures ranging from about 0 degrees Celsius (°C) to about 55°C, more preferable from about 0 °C to about 25 °C.
- the reaction mixture is stirred for a time sufficient to effect the desired completion of the reaction, generally from about 30 minutes to about 24 hours or more.
- the desired steroids of formula (XXV) thus prepared can be recovered by adding water to the reaction mixture, adjusting the pH to neutrality, ie.
- a suitable base such as sodium or potasssium hydroxide
- separating the organic layer containing the desired compound (XXV) from the aqueous layer drying the organic layer over a drying agent such as anhydrous magnesium sulfate (MgSO.4) or sodium sulfate (Na 2 S0 4 ).
- a drying agent such as anhydrous magnesium sulfate (MgSO.4) or sodium sulfate (Na 2 S0 4 ).
- MgSO.4 anhydrous magnesium sulfate
- Na 2 S0 4 sodium sulfate
- the desired steroid (XXV) can be recovered by conventional procedures, such as evaporation of any solvents present, filtration, crystallization, chromatography, distillation and the like.
- the desired steroids of formula (XXX) can be prepared by contacting the reaction media from step (a) containing the steroid of formula (XXV) with water, aqueous alkali or aqueous acid under conditions effective to give the desired steroid of formula (XXX).
- the steroid (XXV) can be separated from the reaction mixture before contacting with " the aqueous media.
- Suitable alkali sources include bases of alkali and alkaline earth metals including carbonates such as sodium, potassium and cesium carbonates; and hydroxides such as sodium or potassium hydroxides.
- the aqueous alkali should be sufficient to adjust the pH of the reaction mixture to between about 9-14.
- Aqueous acid sources include the mineral acids such as hydrochloric, sulfuric, phosphoric and the like.
- the amount of the aqueous acid should be sufficient to adjust the pH of the reaction mixture to between about about 1-4, preferably less than 2. Where water is employed, an amount of water about equivalent to or greater than the amount of solvent employed can be used.
- the steroids of formula (XXX) thus prepared can be recovered by separating the organic layer containing the desired compound (XXX) from the aqueous layer, drying the organic layer over a drying agent such as anhydrous magnesium sulfate (MgS04) or sodium sulfate (Na2S0 4 ) using conventional procedures as described hereinbefore to give the desired steroid (XXX).
- MgS04 anhydrous magnesium sulfate
- Na2S0 4 sodium sulfate
- the steroid of formula (XXX) can be prepared by contacting the compound of formula (XX) with an anhydride and a proton acceptor or an acyl halide and a proton acceptor under conditions effective to yield (XXX).
- Suitable anhydrides are of the formula: (R 10 CO)2 ⁇ wherein R 10 is as defined hereinbefore.
- R 10 is methyl.
- unsymmetrical anhydrides having differing values for R 10 .
- the anhydride can be contacted with the compound of formula (XX) in a ratio ranging from excess to about equimola ⁇ l (moles of anhydride: mole compound of formula (XX)), more preferably from about 50 to 5:1 , most preferably about 40 to 1 :1.
- Suitable acyl halides are of the formula R 10 CO-X wherein R 10 is as defined hereinbefore and X is halo, preferably chloro.
- the acyl halide can be contacted with the compound of formula (XX) in a ratio ranging from about excess to about equimola ⁇ l (moles of acyl halide: mole compound of formula (XX)), more preferably from about 40 to 1 :1.
- Suitable acyl halides include but are not limited to acetyl chloride, propanoyi chloride, trifluoroacetyl chloride, benzoyi chloride, 2-furyl chloride and the like.
- Suitable proton acceptors are represented by amine bases which include the tertiary amines such as 1 ,5-diazabicyclo[4.3.0]non-5- ene (DBN), 4-N,N-dimethylaminopyridine (DMAP), 1,8- diazobicyclo[5.4.0] undec-7-ene (DBU), 1 ,4-diazabicyclo[2.2.2]octane otherwise known as Dabco or triethylenediamine, dimethylaniline, N,N- dimethyl-n-propylamine, N,N-diethylisopropylamine, N- methylpiperidine, N,N-diethylbutylamine; and heterocyclic nitrogen containing compounds such as morpholine, pyridine, imidazole or mixtures of any of the above.
- tertiary amines such as 1 ,5-diazabicyclo[4.3.0]non-5- ene (DBN), 4-N
- the proton acceptor is employed in amounts effective to neutralize acid formed during the reaction.
- the amine base can be contacted with the compound of formula (XX) in a ratio ranging from about 5 to about equimola ⁇ l (moles of acylating catalyst: mole compound of formula (XX)), more preferably from about 2 to 1.
- Process (B) can be carried out neat. When carried out neat, excess amounts of any of the reactants ie. the proton acceptor, acyl halide or anhydride, can be used to solubilize the reaction mixture. Where a solvent is employed, suitable solvents include the aromatic hydrocarbons such as benzene, xylenes and toluenes.
- Process (B) can be conducted at ambient pressures and at temperatures ranging from about ambient to about 150 °C, more preferably from about 80°C to about 105°C.
- the reaction mixture can be stirred for a time sufficient to effect the desired completion of the reaction, generally from about 30 minutes to about 24 hours or more.
- the desired steroids of formula (XXX) thus prepared can be recovered by aqueous washings of the organic reaction mixture, followed by washings with brine.
- the organic layer can be dried over a drying agent such as anhydrous magnesium sulfate (MgS ⁇ 4) or sodium sulfate (Na2S04).
- MgS ⁇ 4 anhydrous magnesium sulfate
- Na2S04 sodium sulfate
- the desired steroid (XXX) can be recovered by conventional procedures as described in Process A.
- reaction mixture is treated with a few drops of water then poured into water (10 ml) and ethylacetate (10 ml). The organic portion is separated, washed with water and saturated sodium bicarbonate solution, dried over magnesium sulfate and evaporated to give the title compound.
- the steroids of formula (XX) are known or can be prepared according to known methods such as described in European Patent Application 87201933.6, Patent Publication 0263569 whose preparative teachings are incorporated herein by reference.
- the steroids of formula (XXi) wherein R1 is -C ⁇ CR 70 are known or can be prepared by contacting a compound of formula (I) with a suitable lithium acetylide compound of the formula LiC ⁇ CR 70 , followed by aqueous or acid hydroloysis to give compound (XXi) as schematically illustrated below:
- R 4 and R 70 are as defined hereinbefore.
- the compound of formula (XXii) wherein R 1 is Ioweralkyi, haloalkyl, phenyl or phenylalkyi can be prepared by contacting the compound of formula (I) with the corresponding organometallic reagent ie.
- organometallic reagent ie. Grignard Reagent or organolithium as taught in J. March, Advanced Organic Chemistry, Reactions, Mechanisms and Structure, Third Edition, John Wiley and Sons, New York, 1985, 1346 pp. as illustrated below:
- R 1b and R 4 are as defined hereinbefore and M is the metal which can be lithium, magnesium and the like.
- PREPARATIVE EXAMPLE 2 1 -(21 -bromo-9 ⁇ .17 ⁇ -dihvdroxv-16 ⁇ -methvl-20-oxopregn-4-en-3- . ylidene ⁇ pyrrolidinium bromide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49913690A | 1990-03-27 | 1990-03-27 | |
| US499,136 | 1990-03-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1991014700A2 true WO1991014700A2 (en) | 1991-10-03 |
| WO1991014700A3 WO1991014700A3 (en) | 1991-11-14 |
Family
ID=23983984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1991/001863 WO1991014700A2 (en) | 1990-03-27 | 1991-03-25 | PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0523132A1 (en) |
| JP (1) | JPH05501115A (en) |
| AU (1) | AU7556291A (en) |
| WO (1) | WO1991014700A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993015103A3 (en) * | 1992-01-28 | 1993-11-25 | Schering Corp | Novel steroid intermediates and processes for their preparation |
| CN106946964A (en) * | 2017-05-04 | 2017-07-14 | 山东赛托生物科技股份有限公司 | A kind of preparation method of the steroid nucleus derivative containing double bond |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU75903A1 (en) * | 1976-09-29 | 1978-05-16 | ||
| US3780177A (en) * | 1967-06-16 | 1973-12-18 | Warner Lambert Co | 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use |
| US3546215A (en) * | 1967-10-18 | 1970-12-08 | Syntex Corp | 6-gem-difluoro steroids |
| GB1416427A (en) * | 1972-01-12 | 1975-12-03 | Akzo Nv | Alkylated pregnanes and process for obtaining same |
| GB1478968A (en) * | 1973-07-11 | 1977-07-06 | Akzo Nv | Alkylated pregnanes |
| US3980778A (en) * | 1973-10-25 | 1976-09-14 | The Upjohn Company | Anti-inflammatory steroid |
| ZA77943B (en) * | 1976-03-19 | 1977-12-28 | Upjohn Co | Topical steroid clindamycin preparations |
| US4088537A (en) * | 1976-06-21 | 1978-05-09 | The Upjohn Company | Δ1 Dehydrogenation of corticoids without side chain degradation by Septomyxa |
| US4127596A (en) * | 1977-04-11 | 1978-11-28 | The Upjohn Company | Non-aromatic oxygenated strong acid dehydration of 9α-hydroxyandrostenediones |
| US4154748A (en) * | 1978-01-20 | 1979-05-15 | The Upjohn Company | Phosphate catalyzed acylation of steroidal tertiary alcohols |
| DE3227312A1 (en) * | 1982-07-19 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | NEW 6.16 DIMETHYL CORTICOIDS, THEIR PRODUCTION AND USE |
| DE3243482A1 (en) * | 1982-11-22 | 1984-05-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | NEW 6 (ALPHA) METHYL CORTICOIDS, THEIR PRODUCTION AND USE |
| DE3401680A1 (en) * | 1984-01-16 | 1985-07-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6 (ALPHA), 16SS DIMETHYL CORTICOIDS |
| DE3434448A1 (en) * | 1984-09-17 | 1986-03-27 | Schering AG, 1000 Berlin und 4709 Bergkamen | METHOD FOR PRODUCING PREGNAN DERIVATIVES |
| DE3783007T2 (en) * | 1986-10-10 | 1993-07-01 | Roussel Uclaf | 9-ALPHA HYDROXYSTEROIDS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF THE CORRESPONDING 9 (11) -DEHYDRO DERIVATIVES. |
| PT87687B (en) * | 1987-06-12 | 1992-09-30 | Gist Brocades Nv | PROCESS FOR THE PREPARATION OF 9 (11) -DEHYROID STEROIDS |
| JPS6471899A (en) * | 1987-09-11 | 1989-03-16 | Nippon Zeon Co | Steroid compound |
-
1991
- 1991-03-25 JP JP3506628A patent/JPH05501115A/en active Pending
- 1991-03-25 EP EP19910907307 patent/EP0523132A1/en not_active Withdrawn
- 1991-03-25 AU AU75562/91A patent/AU7556291A/en not_active Abandoned
- 1991-03-25 WO PCT/US1991/001863 patent/WO1991014700A2/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993015103A3 (en) * | 1992-01-28 | 1993-11-25 | Schering Corp | Novel steroid intermediates and processes for their preparation |
| CN106946964A (en) * | 2017-05-04 | 2017-07-14 | 山东赛托生物科技股份有限公司 | A kind of preparation method of the steroid nucleus derivative containing double bond |
Also Published As
| Publication number | Publication date |
|---|---|
| AU7556291A (en) | 1991-10-21 |
| JPH05501115A (en) | 1993-03-04 |
| EP0523132A1 (en) | 1993-01-20 |
| WO1991014700A3 (en) | 1991-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4041055A (en) | Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes | |
| JP5061061B2 (en) | Process for the preparation of the 17-ester of 9α, 21-dihalo-pregnan-11β, 17α-diol-20-one | |
| US4310467A (en) | Process and intermediates for the synthesis of vitamin D3 metabolites | |
| US7417140B2 (en) | 7α-Hydroxyacetyl and 7α-Hydroperoxyacetyl-substituted steroid compounds | |
| EP1242444A1 (en) | Process for preparing 17alpha-acetoxy-11beta- 4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates | |
| WO1991014700A2 (en) | PROCESS FOR 9α-HYDROXY STEROID DEHYDRATION | |
| US4451404A (en) | 16β-Methyl steroid process | |
| JPH07316184A (en) | 3-alkoxy-18-methyl-3,5-estradien-17-one | |
| US4585591A (en) | 17β-ethynylsteroids and process for preparing same | |
| JPS6337798B2 (en) | ||
| AU636433B2 (en) | Process for dehydrating corticosteroid intermediates | |
| US4213912A (en) | Process for preparing steroidal [16α,17-d]cyclohexene-21-carboxylic acid esters | |
| EP3107925B1 (en) | Process for the production of 21-methoxy-11-beta-phenyl-19-nor-pregna-4,9-diene-3,20-dione derivatives | |
| JP2714392B2 (en) | Method for producing steroid derivatives | |
| JPS6135999B2 (en) | ||
| JPS6115878B2 (en) | ||
| JPS6048998A (en) | Production of pregnan steroid/7alpha-ester compound | |
| JPS6352633B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1991907307 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1991907307 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1991907307 Country of ref document: EP |

















































